Celiac Disease
Conditions
Keywords
Treatment, Active, Celiac, Remission, Induction
Brief summary
This study was conducted to assess the safety and efficacy of larazotide acetate versus placebo in inducing remission in subjects with active celiac disease.
Detailed description
This was an outpatient, randomized, parallel- group, double-blind, multicenter, 8-week study with three treatment arms: larazotide acetate 4 mg TID, larazotide acetate 8 mg TID and placebo TID in subjects with celiac disease. The primary objective was to assess the efficacy of larazotide acetate versus placebo in inducing remission in subjects with active celiac disease, as defined by an improvement in the Villous Height to Crypt Depth (Vh:Cd) ratio, obtained by duodeno-jejunal biopsy. Secondary objectives included assessment of the safety and tolerability of larazotide acetate, to prospectively validate the components of a composite weighted index of celiac disease activity (celiac disease Activity Rating Score, CeDARS), individually and as a whole, to To compare the CeDARS against the Clinician Global Assessment of disease (CGA), Psychological Well Being Index and the Short Form 12 version 2 (SF-12 v2) health survey and to assess the effects of larazotide acetate on inflammatory markers in subjects with active celiac disease.
Interventions
gelatin capsule
DRUGplacebo
gelatin capsule
Sponsors
9 Meters Biopharma, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
double-blind
Intervention model description
randomized, parallel- group, double-blind, multicenter
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male and female adults with celiac disease (as demonstrated by duodenal/jejunal biopsy or by capsule endoscopy plus positive anti-tTG) * Marsh score ≥ II at screening * Positive serum anti-tTG antibodies as determined by screening serology * Willing to comply with a gluten-free diet for the duration of the study
Exclusion criteria
* Has refractory Celiac Disease or severe complications of celiac disease (eg, EATL-, ulcerative jejunitis, perforation, etc.) * Has chronic active GI disease other than Celiac Disease * Has diabetes (Type 1 or Type 2) or other autoimmune disease that might interfere with the conduct of the study * Has hemoglobin value below 8.5 g/dL
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assess the efficacy of larazotide acetate in inducing remission in subjects with active celiac disease | duodeno-jejunal biopsies were performed at Baseline and Day 56 | Remission was defined as an improvement in the Villous Height to Crypt Depth (Vh:Cd) ratio obtained by duodeno-jejunal biopsy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assess the safety and tolerability of larazotide acetate | Up to 8 weeks | Safety endpoints assessed in this study were adverse events, vital signs, physical examination results, clinical laboratory test results and ECG results. Plasma larazotide acetate and metabolites, as well as potential serum antibodies against larazotide acetate, were also determined. |
| To prospectively validate the components of a composite weighted index of Celiac Disease activity (Celiac Disease Activity Rating Score, CeDARS), individually and as a whole. | Up to 8 weeks | Candidate components of the CeDARS Index measured in this study were GSRS, anti-tTG antibodies, LAMA ratio, Hb, ferritin, body weight, triceps skin fold thickness, BMI, urinary nitrates |
| To compare the CeDARS against the Clinician Global Assessment of disease (CGA), Psychological Well Being Index (PWBI) and the Short Form 12 version 2 (SF-12v2) health survey. | CGA, PWBI and SF-12v2 were collected at Visits 2, 3 and 4. | The CGA was completed by the PI or designee; the PWBI and SF-12v2 were completed by the subject. |
| To assess the effects of larazotide acetate on inflammatory markers in subjects with active celiac disease subjects | Blood draws occurred at Visits 1, 2, 3, 4 and 5. | Blood for serum was drawn for potential future determination of inflammatory mediators that might be involved in the response of Celiac Disease to larazotide acetate, such as cytokines (e.g. TNF-α,IFN-γ) or the putative permeability factor zonulin. |
Countries
Canada, Spain, United States
Outcome results
None listed